XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

29 november – 2 december 2016 | Munich, Germany | EORTC-NCI-AACR

┬áThis year in Munich is the 28th @EORTC-NCI-AACR Symposium This event brings together around 2000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in anti cancer drug development, target selection and new discoveries in molecular biology. We will be glad to meet you there. Come and see us at Booth […]

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...